Bioelectronic Medicine is an open-access journal that provides a necessary and specific publication platform for the growing field of Bioelectronic Medicine.
This field brings together material science, biochemistry, biophysics, molecular medicine, neuroscience, immunology, bioengineering, electrical engineering, mechanical engineering, computer science, mathematics, artificial intelligence, and other basic and clinical disciplines. Bioelectronic Medicine promises to bring new insights into the diagnosis and treatment of diseases and conditions as varied as cancer, rheumatoid arthritis, inflammatory bowel disease, obesity, diabetes, asthma, paralysis, blindness, bleeding, ischemia, organ transplantation, cardiovascular disease, neurodegenerative diseases, and others.
Bioelectronic Medicine focuses on electrical signaling in the nervous system. Insights into the regulatory functions of the nervous system and technologies that record, stimulate, or block neural signaling to affect specific molecular mechanisms are the primary focus of the journal. The journal will also feature bioelectronic approaches for monitoring and controlling biological processes, for providing insights into host and pathogen physiology and disease pathogenesis, and for restoring musculoskeletal function and mobility and treating paralysis, and many other conditions. In addition, developments in prostheses, robotics, and other relevant areas will be featured. Innovative preclinical research and development as well as clinical trials assessing new diagnostic and treatment advances will be well represented. Bioelectronic Medicine also welcomes related topics including ethics, community impact, regulatory and legal implications, reimbursement, and patient feedback in order to embrace multidisciplinary input across fields of science, technology, and healthcare.
Criteria to consider for studies involving lnc-RNAs or micro-RNAs:
· The proposed function of the lnc-RNA or miRNA should be validated by gain and loss of function studies.
· Primary cells should be used whenever possible to confirm findings in cell lines.
· In depth investigation in the signaling pathway(s) regulated by the RNA species should be conducted.
· Insight into the regulation of the RNA species and how it relates to the pathologic state should be provided.
· If applicable: Details of initial screen used to identify RNA species involvement in pathway/disease (number of subjects, statistical tests employed, percent change from controls.